News ADC Therapeutics SA

Equities

ADCT

CH0499880968

Market Closed - Nyse Other stock markets 04:00:02 2024-05-10 pm EDT			5-day change	1st Jan Change
4.3 ^USD	-5.91%		-12.24%	+159.04%

May. 07	HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating	MT
May. 06	Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference	May. 09	GL
HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating	May. 07	MT
Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday	May. 06	MT
ADC Therapeutics : 1Q 2024 Earnings Call	May. 06	PU
ADC Therapeutics Launches $105 Million Offering; Shares Up 2% Pre-Bell	May. 06	MT
Transcript : ADC Therapeutics SA, Q1 2024 Earnings Call, May 06, 2024	May. 06
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants	May. 06	GL
ADC Therapeutics SA's Cancer Drug Candidate Shows High Response Rate in Phase 2 Trial	May. 06	MT
ADC Therapeutics SA Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates	May. 06	GL
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma	May. 06	GL
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma	May. 06	CI
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan	May. 01	GL
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024	May. 01	GL
Transcript : ADC Therapeutics SA - Special Call	Apr. 09
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed, Refractory B-cell Non-Hodgkin Lymphoma	Apr. 05	AQ
Sector Update: Health Care Stocks Slump Late Afternoon	Apr. 04	MT
ADC Therapeutics Shares Rise After Completion of Dose Escalation Part of Phase 1b Lymphoma Trial	Apr. 04	MT
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma	Apr. 04	GL
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024	Apr. 03	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ADC Therapeutics SA

Equities

ADCT

CH0499880968

Summary

Filters